Mulhouse, France – February 12, 2026 – CellProthera today announced the acquisition of the transendocardial catheter originally developed by Celyad Oncology.
CYAD) (“Celyad” or the “Company”), today announced the acquisition by CellProthera of C-Cathez®, the transendocardial catheter originally developed by Celyad Oncology ... this sale of the catheter.
indications for aspiration catheters ...Food and Drug Administration (FDA) 510(k) clearance expanding the indications of its neurovascular and peripheral aspiration catheters to include distal access.
BioCardia Files Pre-Submission for FDA Approval of Helix™ Transendocardial DeliveryCatheter for Therapeutic and Diagnostic Agent Delivery to the Heart... About the Helix Transendocardial Delivery Catheter.
Catheter Kit Fraud ...Maria Alvarez, Executive Director of StateWide, advises, "Medicare beneficiaries across the country are discovering charges for urinary catheter kits they did not need, did not request, and never received.
Catheter stabilization solutions are applied across a broad range of catheter types, including urinary catheters, central venous catheters, peripherally inserted central catheters, arterial lines, feeding tubes, and epidural catheters.